Patient-derived organoids enable ex vivo drug-response profiling for precision medicine in bladder cancer
Patient-derived organoids (PDOs) represent a promising precision medicine approach for replicating primary tumor characteristics and facilitating drug testing across various cancers, although clinical evidence in bladder cancer remains limited. This study evaluates the impact of incorporating PDOs into clinical pract...